Price
$1.88
Decreased by -6.47%
Dollar Volume
394.67 K
ADR%
11.75
Earnings Report Date (estimate)
Nov 14, 22 (N/A)
Market Cap.
14.00 M
Shares Float
7.35 M
Shares Outstanding
7.45 M
Beta
0.28
Price / Earnings
6.27
BPR
3.11
20D Range
1.76 2.98
50D Range
1.76 4.80
200D Range
1.76 9.60
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.94
Increased by +32.86%
-1.20
Increased by +21.67%
Aug 11, 22 9.60
Increased by +700.00%
-1.40
Increased by +785.71%
May 16, 22 -1.20
Increased by +25.00%
-1.20
Mar 10, 22 -1.20
Increased by +40.00%
-1.40
Increased by +14.29%
Nov 15, 21 -1.40
Increased by +30.00%
-1.40
Aug 16, 21 -1.60
Increased by 0.00%
-1.60
May 17, 21 -1.60
Increased by +60.00%
-1.60
Mar 15, 21 -2.00
Increased by +44.44%
-2.00
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 507.00 K
Decreased by -72.77%
-6.75 M
Increased by +19.40%
Decreased by -1.33 K%
Decreased by -196.00%
Jun 30, 22 570.00 K
Increased by +28.67%
70.66 M
Increased by +817.32%
Increased by +12.40 K%
Increased by +657.49%
Mar 31, 22 442.00 K
Decreased by -13.50%
-8.67 M
Increased by +3.15%
Decreased by -1.96 K%
Decreased by -11.97%
Dec 31, 21 2.00 K
Decreased by -99.73%
-7.92 M
Increased by +11.22%
Decreased by -395.85 K%
Decreased by -32.66 K%
Sep 30, 21 1.86 M
Increased by +36.11%
-8.38 M
Increased by +6.22%
Decreased by -449.79%
Increased by +31.10%
Jun 30, 21 443.00 K
Decreased by -84.85%
-9.85 M
Decreased by -49.12%
Decreased by -2.22 K%
Decreased by -884.27%
Mar 31, 21 511.00 K
Increased by +32.38%
-8.96 M
Increased by +43.76%
Decreased by -1.75 K%
Increased by +57.52%
Dec 31, 20 738.00 K
Increased by +55.37%
-8.92 M
Increased by +38.17%
Decreased by -1.21 K%
Increased by +60.20%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.